| P2093 | author name string | Donald J Tindall | |
| | Ji Lu | |
| | Travis Van der Steen | |
| P2860 | cites work | Nuclear receptor structure: implications for function | Q36669652 |
| | Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. | Q36681101 |
| | Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression | Q36807948 |
| | Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth | Q36876865 |
| | An androgen receptor N-terminal domain antagonist for treating prostate cancer. | Q36966859 |
| | Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions | Q36971803 |
| | Posttranslational modification of the androgen receptor in prostate cancer | Q37092022 |
| | Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. | Q37093536 |
| | Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance | Q37145531 |
| | Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors | Q37488488 |
| | FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants | Q37560428 |
| | Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium | Q37656304 |
| | The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells | Q38965060 |
| | Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor | Q38971752 |
| | Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues. | Q39020826 |
| | NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants | Q39148465 |
| | The role of DAB2IP in androgen receptor activation during prostate cancer progression | Q39162930 |
| | Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines | Q39250655 |
| | Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. | Q39329100 |
| | AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells | Q39390992 |
| | Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance. | Q39429490 |
| | Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression | Q39605639 |
| | Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. | Q39647282 |
| | The androgen receptor gene mutations database: 2012 update. | Q39652410 |
| | Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. | Q39787201 |
| | Steroid hormone receptors in prostate cancer: a hard habit to break? | Q39922512 |
| | Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer | Q39954334 |
| | Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence | Q40073673 |
| | A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. | Q40125649 |
| | A naturally derived small molecule disrupts ligand-dependent and ligand-independent androgen receptor signaling in human prostate cancer cells | Q42006737 |
| | Shortened isoforms of the androgen receptor are regulated by the cytoprotective heat-shock protein HSPB1 and the tumor-suppressive microRNA miR-1 in prostate cancer cells | Q44235399 |
| | Mechanisms of androgen-refractory prostate cancer | Q45094999 |
| | Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression | Q46470624 |
| | Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. | Q47383290 |
| | Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. | Q53170054 |
| | IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis | Q79342871 |
| | Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer | Q94358725 |
| | Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival | Q21091046 |
| | Androgen receptor variants occur frequently in castration resistant prostate cancer metastases | Q21558502 |
| | Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor | Q24319189 |
| | AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer | Q27853062 |
| | Cancer statistics, 2014 | Q27861018 |
| | A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth | Q28116222 |
| | Molecular determinants of resistance to antiandrogen therapy | Q28236889 |
| | The development of androgen-independent prostate cancer | Q29615650 |
| | Androgen receptor in prostate cancer | Q29616454 |
| | Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer | Q30485336 |
| | Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant | Q30495758 |
| | AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression | Q30513836 |
| | AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer | Q30544584 |
| | TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. | Q30554439 |
| | Androgen receptor splice variants determine taxane sensitivity in prostate cancer | Q30577613 |
| | ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines | Q33593873 |
| | Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy | Q33688956 |
| | Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex | Q34007618 |
| | Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor | Q34165500 |
| | Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer | Q34249190 |
| | The role of epithelial plasticity in prostate cancer dissemination and treatment resistance | Q34505037 |
| | Contribution of the androgen receptor to prostate cancer predisposition and progression | Q34708708 |
| | Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells | Q34713218 |
| | Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer | Q35150756 |
| | Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants | Q35249697 |
| | Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells. | Q35372023 |
| | Alternatively spliced androgen receptor variants | Q35606969 |
| | ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. | Q35763908 |
| | A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities | Q35990121 |
| | Mechanisms of the androgen receptor splicing in prostate cancer cells | Q36005683 |
| | Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival | Q36454548 |
| | New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells | Q36582853 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 137-144 | |
| P577 | publication date | 2015-02-10 | |
| P1433 | published in | Nature Reviews Urology | Q2079265 |
| P1476 | title | Are androgen receptor variants a substitute for the full-length receptor? | |
| P478 | volume | 12 | |